Guidelines & Papers
Guidelines
Diagnosis of Idiopathic Pulmonary Fibrosis
- Raghu G, Remy‑Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44‑e68. doi:10.1164/rccm.201807‑1255ST.
Diagnosis of Hypersensitivity Pneumonitis in Adults
- Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Executive Summary: Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36-e69. doi:10.1164/rccm.202005-2032ST.
Diagnosis of Hypersensitivity Pneumonitis in Adults, 2020 Clinical Practice Guideline
- Koster MA, Raghu G. Diagnosis of hypersensitivity pneumonitis in adults, 2020 clinical practice guideline: summary for clinicians. Ann Am Thorac Soc. 2021;18(4):559-566. doi:10.1513/AnnalsATS.202009-1195CME
Standardized Clinical Terms and Definitions for Interstitial Lung Disease: A Consensus Statement from the Fleischner Society
- Ryerson CJ, Bankier A, Beasley MB, et al. Standardized clinical terms and definitions for interstitial lung disease: a consensus statement from the Fleischner Society. Am J Respir Crit Care Med. 2025;211(10):1756-1774. doi:10.1164/rccm.202505-1142SO
Treatment Related Papers
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. doi:10.1056/NEJMoa1402584
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
- Flaherty KR, Wells AU, Brown KK, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. doi:10.1056/NEJMoa1908681
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- Distler O, Highland KB, Gahlemann M, et al; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis–associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092. doi:10.1056/NEJMoa14025
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
- Richeldi L, Azuma A, Cottin V, et al; FIBRONEER-IPF Investigators. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2025;392(22):2193-2202. doi:10.1056/NEJMoa2414108
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
- Maher TM, Assassi S, Azuma A, et al; FIBRONEER‑IPF Investigators. Nerandomilast in patients with progressive pulmonary fibrosis. N Engl J Med. 2025;392(22):2203‑2214. doi:10.1056/NEJMoa2503643